1. Search Result
Search Result
Results for "

Acute respiratory distress syndrome

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

2

Biochemical Assay Reagents

3

Peptides

4

Inhibitory Antibodies

2

Natural
Products

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17443
    Sivelestat
    Maximum Cited Publications
    30 Publications Verification

    EI546; LY544349; ONO5046

    Elastase SARS-CoV Cancer
    Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    Sivelestat
  • HY-155876

    NLRP3 antagonist 2

    NOD-like Receptor (NLR) Infection Inflammation/Immunology
    NVP-DFV890 is an orally administered, selective NLRP3 inhibitor. NVP-DFV890 directly binds to NLRP3, blocks maturation of pro-inflammatory cytokines IL-1β and IL-18, and inhibits pyroptotic cell death. NVP-DFV890 acts as an inducer of viral clearance, promoting earlier clearance of SARS-CoV-2. NVP-DFV890 can be used for the research of COVID-19 pneumonia and coronavirus-associated acute respiratory distress syndrome (CARDS) .
    NVP-DFV890
  • HY-17443A
    Sivelestat sodium
    Maximum Cited Publications
    30 Publications Verification

    ONO5046-Na; Sodium sivelestat; EI546 sodium; LY544349 sodium

    Elastase SARS-CoV Cancer
    Sivelestat (EI546) sodium is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    Sivelestat sodium
  • HY-NP004

    CVF

    Complement System Inflammation/Immunology
    Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) .
    Cobra Venom Factor
  • HY-17443B
    Sivelestat sodium tetrahydrate
    Maximum Cited Publications
    30 Publications Verification

    EI546 sodium tetrahydrate; LY544349 sodium tetrahydrate; ONO5046 sodium tetrahydrate

    Elastase SARS-CoV Cancer
    Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    Sivelestat sodium tetrahydrate
  • HY-P99810

    AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002

    SARS-CoV Infection Inflammation/Immunology
    Quisovalimab (AVTX-002) is a human-derived monoclonal antibody against LIGHT (TNFSF14). Quisovalimab binds to LIGHT, blocks the signal transduction activity of LIGHT, reduces circulating LIGHT levels and attenuates pro-inflammatory effects. Quisovalimab can be used in research related to Crohn's disease, COVID-19-associated pneumonia and acute respiratory distress syndrome comorbidity .
    Quisovalimab
  • HY-P990094

    CSL311

    c-Fms Inflammation/Immunology
    Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps .
    Trabikibart
  • HY-P991401

    TNF Receptor Inflammation/Immunology
    GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc .
    GSK2862277
  • HY-12716A

    Adrenergic Receptor ERK p38 MAPK Dopamine Receptor Cardiovascular Disease Neurological Disease
    BRL-44408 maleate is a selective, blood-brain barrier-permeable α2A-adrenergic receptor antagonist with a Ki value of 8.56 nM against human targets. BRL-44408 maleate exhibits activities such as antidepressant, analgesic effects and attenuation of sepsis-induced acute lung injury by regulating the release of neurotransmitters such as norepinephrine and dopamine, or inhibiting signaling pathways including ERK1/2, p38MAPK and p65. BRL-44408 maleate can be used in studies related to acute respiratory distress syndrome, depression and visceral pain .
    BRL-44408 maleate
  • HY-D0227J

    Tris HCl (≥99%, for cell culture); Tris hydrochloride (≥99%, for cell culture)

    Biochemical Assay Reagents Metabolic Disease
    THAM hydrochloride (≥99%, for cell culture) is a low-toxicity amino alcohol buffer, a specific CO2-consuming proton acceptor that buffers carbon dioxide and acid both in vitro and in vivo. THAM hydrochloride (≥99%, for cell culture) binds protons to form bicarbonate, reduces PaCO2, and induces intracellular alkalization, thereby ameliorating hypercapnia-induced elevation of pulmonary blood vessels and pulmonary arterial pressure. THAM hydrochloride (≥99%, for cell culture) may cause PaCO2 rebound, hypoglycemia, and respiratory depression. THAM hydrochloride (≥99%, for cell culture) removes amniotic epithelium and preserves the basement membrane, but depletes extracellular matrix and reduces the adhesion rate of limbal epithelial cells. THAM hydrochloride (≥99%, for cell culture) can act as a CO2 carrier to enhance the productivity and carbon utilization rate of Scenedesmus obliquus. THAM hydrochloride (≥99%, for cell culture) is a key component of buffer solutions used in various biological, cell culture, biochemical, and molecular biology applications .
    THAM hydrochloride (≥99%, for cell culture)
  • HY-150735

    IRAK Inflammation/Immunology
    IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research .
    IRAK4-IN-20
  • HY-N7372

    Apoptosis Infection Inflammation/Immunology
    Licoisoflavanone is an orally active isoflavane-based immunomodulator with multiple activities including antiviral, anti-inflammatory, cytoprotective and cancer cell apoptosis-inducing effects. Licoisoflavanone can be isolated from the roots and rhizomes of Glycyrrhiza uralensis Fisch. Licoisoflavanone not only enhances the body's immunity, but also effectively prevents acute respiratory distress syndrome and multiple organ damage by alleviating cytokine storm, thereby reducing the degree of inflammation. In rats, Licoisoflavanone undergoes multiple metabolic transformation processes such as glucuronidation, hydroxylation, sulfation, methylation and dehydrogenation. Licoisoflavanone has become an important candidate molecule for research on COVID-19 and related inflammatory diseases .
    Licoisoflavanone
  • HY-178136

    Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB JNK Infection Inflammation/Immunology
    MyD88-IN-3 is an orally active, selective MyD88 Inhibitor. MyD88-IN-3 specifically targets the TIR domain of MyD88 (KD = 28.5 μM), thereby preventing MyD88 self-polymerization and interaction with TLRs, which suppresses the activation of MAPK and NF-κB pathways. MyD88-IN-3 demonstrates significant anti-inflammatory efficacy and effectively mitigates Acute Lung Injury (ALI) symptoms in CLP (cecal ligation and puncture) and Lipopolysaccharides (HY-D1056) (LPS)-induced ALI models. MyD88-IN-3 can be used for the study of ALI .
    MyD88-IN-3
  • HY-12716

    Adrenergic Receptor p38 MAPK Dopamine Receptor ERK Cardiovascular Disease Neurological Disease
    BRL-44408 is a selective, blood-brain barrier-permeable α2A-adrenergic receptor antagonist with a Ki value of 8.56 nM against human targets. BRL-44408 exhibits activities such as antidepressant, analgesic effects and attenuation of sepsis-induced acute lung injury by regulating the release of neurotransmitters such as norepinephrine and dopamine, or inhibiting signaling pathways including ERK1/2, p38MAPK and p65. BRL-44408 can be used in studies related to acute respiratory distress syndrome, depression and visceral pain .
    BRL-44408
  • HY-D0227B
    THAM acetate
    1 Publications Verification

    Tris acetate; Tris(hydroxymethyl)aminomethane acetate

    Biochemical Assay Reagents Metabolic Disease
    THAM acetate is a low-toxicity amino alcohol buffer, a CO2-consuming proton acceptor that buffers carbon dioxide and acid both in vitro and in vivo. THAM acetate binds protons to form bicarbonate, reduces PaCO2, and induces intracellular alkalization, thereby ameliorating hypercapnia-induced elevation of pulmonary blood vessels and pulmonary arterial pressure. THAM acetate may cause PaCO2 rebound, hypoglycemia, and respiratory depression. THAM acetate removes amniotic epithelium and preserves the basement membrane, but depletes extracellular matrix and reduces the adhesion rate of limbal epithelial cells. THAM acetate can act as a CO2 carrier to enhance the productivity and carbon utilization rate of Scenedesmus obliquus. THAM acetate is a key component of buffer solutions used in various biological, cell culture, biochemical, and molecular biology applications .
    THAM acetate
  • HY-159159

    NOD-like Receptor (NLR) Inflammation/Immunology
    MS-II-124 is an effective and selective NLRP3 inhibitor (IC50=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) .
    MS-II-124
  • HY-145390A

    Keap1-Nrf2 Inflammation/Immunology
    (R,R)-Nrf2 activator-1 is the enantiomer of Nrf2 activator-1. Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis .
    (R,R)-Nrf2 activator-1
  • HY-17443R

    EI546 (Standard); LY544349 (Standard); ONO5046 (Standard)

    Elastase SARS-CoV Reference Standards Cancer
    Sivelestat (Standard) is the analytical standard of Sivelestat. This product is intended for research and analytical applications. Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    Sivelestat (Standard)
  • HY-P10889

    Phosphatase Inflammation/Immunology
    CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (KD=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases .
    CNI103
  • HY-106377

    MARCKS Inflammation/Immunology
    BIO-11006 is a peptide that inhibits the function of the MARCKS protein. BIO-11006 attenuates LPS-induced neutrophil influx into the lungs, NF-κB activation, and expression of the proinflammatory cytokines KC and TNF-α. BIO-11006 also reverses disease progression in an LPS-induced mouse lung injury model. BIO-11006 is indicated for research on acute lung injury/acute respiratory distress syndrome (ALI/ARDS) .
    BIO-11006
  • HY-108623

    CP-80,633

    Phosphodiesterase (PDE) Inflammation/Immunology
    Atizoram (CP-80,633) is an orally active phosphodiesterase type 4 (PDE4) inhibitor. Atizoram blocks cAMP degradation, thereby increasing intracellular and plasma cAMP levels. Atizoram inhibits TNFα release. Atizoram can be used in research related to acute respiratory distress syndrome .
    Atizoram
  • HY-145390

    Keap1-Nrf2 Inflammation/Immunology
    Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1) .
    Nrf2 activator-1
  • HY-P991612

    Sym024

    CD73 Inflammation/Immunology Cancer
    S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
    S095024
  • HY-W749980A

    cis-9,10-Epoxy-12(Z)-octadecenoic acid

    Endogenous Metabolite Others
    cis-Coronaric acid is the 9,10-cis epoxide of linoleic acid, generated by neutrophils during the oxidative burst. It has been recovered from the lungs of hyperoxic rats and from humans with acute respiratory distress syndrome. Mitochondrial dysfunction is the main feature of cis-Coronaric acid cytotoxicity, which may be due to the diol metabolites as well as the parent epoxide.
    cis-Coronaric acid
  • HY-17443BR

    EI546 sodium tetrahydrate (Standard); LY544349 sodium tetrahydrate (Standard); ONO5046 sodium tetrahydrate (Standard)

    Reference Standards Elastase SARS-CoV Cancer
    Sivelestat (sodium tetrahydrate) (Standard) is the analytical standard of Sivelestat (sodium tetrahydrate). This product is intended for research and analytical applications. Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    Sivelestat sodium tetrahydrate (Standard)
  • HY-116462

    Drug Metabolite Others
    ONO-EI-601 is the major metabolite of human neutrophil elastase inhibitor ONO-5046. ONO-5046 has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .
    ONO-EI-601
  • HY-N13798

    NF-κB Biochemical Assay Reagents Inflammation/Immunology
    ADHPE is a stabilizer of 14-3-3σ and p65 protein complex. ADHPE inhibits NF-κB (p65) signaling pathway and reduces the inflammatory response. ADHPE can be used for pediatric pneumonia-related acute lung injury and acute respiratory distress syndrome study .
    ADHPE
  • HY-149052

    RIP kinase Mixed Lineage Kinase Necroptosis Inflammation/Immunology
    SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects .
    SZM-1209
  • HY-P11791

    Endogenous Metabolite Infection
    nNIF peptide is an endogenous polypeptide detectable in human umbilical cords and neonatal blood. nNIF peptide specifically inhibits neutrophil extracellular trap (NETs) formation by neutrophils without interfering with other key immune functions of neutrophils. nNIF peptide can be used in studies related to COVID-19 acute respiratory distress syndrome, polymicrobial sepsis, and neonatal infectious peritonitis .
    nNIF peptide
  • HY-112042

    Drug Intermediate Infection Cardiovascular Disease Inflammation/Immunology
    Aspirin Trelamine is a salicylic acid prodrug. Aspirin Trelamine has been used in research related to ischemic stroke, as well as COVID-19-associated acute respiratory distress syndrome (ARDS) and pneumonia .
    Aspirin Trelamine
  • HY-P11879

    Infection Inflammation/Immunology Endocrinology
    LSALT peptide is a selective DPEP-1 inhibitor with selectivity over DPEP2/3. LSALT peptide inhibits neutrophil and monocyte/macrophage recruitment, inflammation, and tissue injury. LSALT peptide reduces kidney damage, improves survival in murine sepsis and endotoxemia models. LSALT peptide can be used for the research of COVID-19, sepsis, acute respiratory distress syndrome, and acute kidney injury .
    LSALT peptide
  • HY-175217

    Keap1-Nrf2 Cardiovascular Disease Inflammation/Immunology
    Nrf2 activator-20 is a potent Nrf2 activator with anti-inflammatory and antioxidant activities. Nrf2 activator-20 activates the anti-inflammatory pathway by interfering with the Keap1-Nrf2 interaction and is beneficial in vivo. Nrf2 activator-20 can be used for the study of acute respiratory distress syndrome (ARDS) and ischemia-reperfusion injury .
    Nrf2 activator-20

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: